valproic acid has been researched along with Anterior Choroidal Artery Infarction in 11 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| "Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| "In all the patients with cerebral infarction, the current arrows exhibited the similar pattern as the normal subjects." | 1.31 | Cortical functional abnormality assessed by auditory-evoked magnetic fields and therapeutic approach in patients with chronic dizziness. ( Kandori, A; Miyashita, K; Murakami, M; Naritomi, H; Oe, H; Tsukada, K, 2002) |
| "Pretreatment with phenytoin and carbamazepine prevented a reduction of this activity, which, without either treatment, was observed in the cerebral hemisphere exposed to 30-minute ischemia resulting from unilateral middle cerebral artery occlusion." | 1.29 | Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodium-potassium-adenosine triphosphatase in acute ischemic brain. ( Furui, T; Murakami, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, S | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hashmi, MA | 1 |
| Wang, Z | 1 |
| Tsai, LK | 1 |
| Munasinghe, J | 1 |
| Leng, Y | 2 |
| Fessler, EB | 1 |
| Chibane, F | 1 |
| Leeds, P | 1 |
| Chuang, DM | 3 |
| Oe, H | 1 |
| Kandori, A | 1 |
| Murakami, M | 1 |
| Miyashita, K | 1 |
| Tsukada, K | 1 |
| Naritomi, H | 1 |
| Ren, M | 2 |
| Jeong, M | 1 |
| Leeds, PR | 1 |
| Kikuta, K | 1 |
| Takagi, Y | 1 |
| Arakawa, Y | 1 |
| Miyamoto, S | 1 |
| Hashimoto, N | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Murakami, A | 1 |
| Furui, T | 1 |
| Gnam, W | 1 |
| Flint, AJ | 1 |
| Kehne, JH | 1 |
| Kane, JM | 1 |
| Chaney, SF | 1 |
| Hurst, G | 1 |
| McCloskey, TC | 1 |
| Petty, MA | 1 |
| Senyah, Y | 1 |
| Wolf, HH | 1 |
| Zobrist, R | 1 |
| White, HS | 1 |
| Minato, H | 1 |
| Kikuta, C | 1 |
| Fujitani, B | 1 |
| Masuda, Y | 1 |
| Matsuda, Y | 1 |
| Neshige, R | 1 |
| Endo, C | 1 |
| Abe, M | 1 |
| Kuroda, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
11 other studies available for valproic acid and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I | 2011 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Cortical functional abnormality assessed by auditory-evoked magnetic fields and therapeutic approach in patients with chronic dizziness.
Topics: Acoustic Stimulation; Aged; Anticonvulsants; Auditory Cortex; Auditory Diseases, Central; Brain Mapp | 2002 |
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Topics: Acetylation; Animals; Behavior, Animal; Caspase 3; Caspases; Cerebral Cortex; Cerebral Infarction; D | 2004 |
Absence epilepsy associated with moyamoya disease. Case report.
Topics: Anticonvulsants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Cerebral | 2006 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodium-potassium-adenosine triphosphatase in acute ischemic brain.
Topics: Animals; Carbamazepine; Cerebral Cortex; Cerebral Infarction; Dose-Response Relationship, Drug; Male | 1994 |
New onset rapid cycling bipolar disorder in an 87 year old woman.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Cerebral Infarction; Female; Humans; Hypothyroidism; Lith | 1993 |
Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties.
Topics: Animals; Anticonvulsants; Cerebral Infarction; Craniocerebral Trauma; Electroshock; Injections, Intr | 1997 |
Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats.
Topics: Animals; Anticonvulsants; Arterial Occlusive Diseases; Body Temperature; Carbamazepine; Cerebral Art | 1997 |
[A case of upper brainstem infarction developing symptomatic narcolepsy after the administration of anti-convulsant drugs].
Topics: Brain Stem; Cerebral Infarction; Electroencephalography; Female; Humans; Magnetic Resonance Imaging; | 1991 |